Compare ACNB & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNB | VOR |
|---|---|---|
| Founded | 1857 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.4M | 755.7M |
| IPO Year | 1994 | 2021 |
| Metric | ACNB | VOR |
|---|---|---|
| Price | $51.12 | $15.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $52.00 | $45.44 |
| AVG Volume (30 Days) | 51.3K | ★ 1.2M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.60 | N/A |
| Revenue | ★ $191,821,000.00 | N/A |
| Revenue This Year | $13.18 | N/A |
| Revenue Next Year | $1.91 | N/A |
| P/E Ratio | $14.25 | ★ N/A |
| Revenue Growth | ★ 45.10 | N/A |
| 52 Week Low | $39.75 | $0.13 |
| 52 Week High | $53.89 | $49.95 |
| Indicator | ACNB | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 55.16 |
| Support Level | $48.40 | $11.38 |
| Resistance Level | $53.71 | $16.88 |
| Average True Range (ATR) | 1.07 | 1.63 |
| MACD | 0.53 | 0.05 |
| Stochastic Oscillator | 81.53 | 50.81 |
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.